Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pinato

Showing results (101-110 of 238) with videos related to

Pageof 24
Sort By:
Journal for Immunotherapy of Cancer|February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumorsJason J Luke, David J Pinato, Dejan Juric, et al.
Cancers|May 5, 2021
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular CarcinomaPetros Fessas, Paolo Spina, Renzo L Boldorini, et al.
International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
British Journal of Cancer|May 8, 2019
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC studyDavid J Pinato, Francesco A Mauri, Paolo Spina, et al.
International Journal of Molecular Sciences|January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker StudyShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
British Journal of Cancer|August 22, 2022
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancerAlessio Cortellini, Juan Aguilar-Company, Ramon Salazar, et al.
British Journal of Cancer|June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasmsT R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
The Lancet. Oncology|July 6, 2023
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
Pageof 24

Showing results (101-110 of 238) with videos related to

Sort By:
Pageof 24
Journal for Immunotherapy of Cancer|February 20, 2025
Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumorsJason J Luke, David J Pinato, Dejan Juric, et al.
Cancers|May 5, 2021
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular CarcinomaPetros Fessas, Paolo Spina, Renzo L Boldorini, et al.
International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.
British Journal of Cancer|May 8, 2019
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC studyDavid J Pinato, Francesco A Mauri, Paolo Spina, et al.
International Journal of Molecular Sciences|January 21, 2023
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker StudyShobana Anpalakhan, Prerana Huddar, Roya Behrouzi, et al.
British Journal of Cancer|August 22, 2022
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancerAlessio Cortellini, Juan Aguilar-Company, Ramon Salazar, et al.
British Journal of Cancer|June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasmsT R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
The Lancet. Oncology|July 6, 2023
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy conceptAlessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
JHEP Reports : Innovation in Hepatology|May 17, 2023
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinomaDavid J Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, et al.
Pageof 24